title: Serum Pentraxin-3 Level in Patients Who Underwent Coronary Angiography and Relationship with Coronary Atherosclerosis.
abstract: OBJECTIVE
  To evaluate the role of pentraxin-3 (PTX-3) in determining the presence and severity of coronary atherosclerosis in patients with coronary artery disease (CAD).
  
  
  METHODS
  Ninety-five patients (77 males and 18 females) who underwent elective coronary angiography were enrolled in this study. Patients with heart failure, renal failure, diabetes and thyroid disease were excluded. The study population was divided into 3 groups: individuals with normal coronary arteries, patients with critical CAD (n = 35) and patients with noncritical CAD (n = 36). The association of PTX-3 levels with the presence and severity of CAD and the number of involved vessels were analyzed.
  
  
  RESULTS
  The mean age was 53.40 ± 10.25 years. The PTX-3 levels were significantly higher in patients with CAD than without CAD (146.48 ± 48.52 vs. 109.83 ± 49.06 pg/ml, p < 0.001). A statistically significant difference was found among the 3 groups regarding the severity of CAD (165.66 ± 49.10, 127.83 ± 40.51 and 109.83 ± 49.06 pg/ml, p < 0.001, respectively). The serum PTX-3 levels in normal arteries were 110.4 ± 48.11 pg/ml, in single-vessel disease 132.35 ± 32.96 pg/ml, in 2-vessel disease 142.57 ± 55.88 pg/ml, in 3-vessel disease 156.07 ± 50.53 pg/ml, and in 3-vessel disease 160.50 ± 30.41 pg/ml. After adjusting for baseline confounders, older age (OR = 1.107, 95% CI = 1.027-1.193, p = 0.008) and higher PTX-3 levels (OR = 1.017, 95% CI = 1.003-1.032, p = 0.021) were detected as significant predictors for the presence of CAD.
  
  
  CONCLUSIONS
  Higher PTX-3 levels were associated with the presence of CAD and its increased severity in clinically stable patients. Higher PTX-3 levels may be regarded as a novel diagnostic predictor and may offer therapeutic options in the clinic.
authors.affiliation: Balmumcu Family Health Center, Gumussuyu Military Hospital, Istanbul, Turkey.
authors.forename: Polat
authors.initials: P
authors.lastname: Nerkiz
authors.forename: Yusuf Cetin
authors.initials: YC
authors.lastname: Doganer
authors.forename: Umit
authors.initials: U
authors.lastname: Aydogan
authors.forename: Halil
authors.initials: H
authors.lastname: Akbulut
authors.forename: Adem
authors.initials: A
authors.lastname: Parlak
authors.forename: Aydogan
authors.initials: A
authors.lastname: Aydogdu
authors.forename: Oktay
authors.initials: O
authors.lastname: Sari
authors.forename: Tuncer
authors.initials: T
authors.lastname: Cayci
authors.forename: Cem
authors.initials: C
authors.lastname: Barcin
authors.forename: Bayram
authors.initials: B
authors.lastname: Koc
mesh_terms: D000328:Adult; D000367:Age Factors; D015415:Biomarkers; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000000981:diagnostic imaging* / Q000453:epidemiology; D050171:Dyslipidemias / Q000453:epidemiology; D005260:Female; D005919:Glomerular Filtration Rate; D006403:Hematologic Tests; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D000683:Serum Amyloid P-Component / Q000032:analysis*; D012720:Severity of Illness Index; D012737:Sex Factors; D012907:Smoking / Q000453:epidemiology; D000099153:Pentraxins
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein; D000683:Serum Amyloid P-Component; D000099153:Pentraxins